摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Sulfanilamido-pyrimidin | 599-82-6

中文名称
——
中文别名
——
英文名称
4-Sulfanilamido-pyrimidin
英文别名
4-Sulfapyrimidin;4-amino-N-(pyrimidin-4-yl)benzenesulfonamide;4-amino-N-pyrimidin-4-ylbenzenesulfonamide
4-Sulfanilamido-pyrimidin化学式
CAS
599-82-6
化学式
C10H10N4O2S
mdl
——
分子量
250.281
InChiKey
PXDBUWPMANSAFI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    106
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-Sulfanilamido-pyrimidin盐酸溶剂黄146 、 sodium nitrite 作用下, 反应 5.0h, 生成
    参考文献:
    名称:
    Jain, Rajeev; Padmaja; Bhadauria, Jyoti, Journal of the Indian Chemical Society, 2000, vol. 77, # 1, p. 42 - 43
    摘要:
    DOI:
  • 作为产物:
    描述:
    对硝基苯磺酰氯铁粉 盐酸 作用下, 以 吡啶乙醇 为溶剂, 反应 5.0h, 生成 4-Sulfanilamido-pyrimidin
    参考文献:
    名称:
    [EN] MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF
    [FR] MODULATEURS DU RÉCEPTEUR IMMUNOSUPPRESSEUR PD-1 ET PROCÉDÉS D'UTILISATION DE CEUX-CI
    摘要:
    公开号:
    WO2011082400A3
点击查看最新优质反应信息

文献信息

  • Sulfonamido pyrimidines
    申请人:AMERICAN CYANAMID CO
    公开号:US02430439A1
    公开(公告)日:1947-11-04

    555,865. Sulphonamido pyrimidines. AMERICAN CYANAMID CO. March 8, 1941, Nos. 3174 and 3175. Convention dates, March 1, 1940 and Oct. 15, 1940. Samples furnished. [Class 2 (iii)] p-Substituted benzene-sulphonamido-pyrimidenes are made by reacting a benzene-sulphonyl halide, e.g. a chloride substituted in the para position by an amino group or a group convertible thereto by hydrolysis, reduction or by reaction with ammonia or an amine such as an acylamino, nitro, halogen or azo group, with an amino-pyrimidine. The products are of the general formula where R is a halogen, nitro, azo, amino or substituted amino group, e.g. alkylamino, arylamino, aralkylamino, acylamino or monoaldose amino, X is H, an alkyl group or a metal, Py is a pyrimidine substituted or unsubstituted and n is a small integer. The mono-aldose amino compounds are'made from the corresponding amino compounds by reaction with a mono aldose sugar such as galactose or glucose preferably in a solvent such as ethanol. Free hydrogen halide obtained during the reaction with a sulphonyl halide is removed by effecting the reaction in a basic medium, e.g. aqueous sodium hydroxide, triethylamine and pyridine and solvents, e.g. dioxane, acetone and benzene are specified. Alkali metal or heavy metal, e.g. gold, lead, copper and iron, salts of the products are also described. Examples describe the preparation of the following compounds by the above methods (1) 5-(N<;SP>;4<;/SP>;- acetylsulphanilamido) - 2, 4 - dihydroxy-, (2) 5 - (sulphanilamido) - 2, 4 - dihydroxy-, (3) 5 - (p - nitrobenzene sulphonamido) - 2, 4 - dihydroxy-, (4) 5 - (N<;SP>;4<;/SP>; -acetylsulphanil - - amido)-, (5) 5 - (sulphanilamido)-, (6) 4 - (p - nitrobenzenesulphonamido)-, (7) and (9) 4 - (sulphanilamido)-, (8) 4 - (N<;SP>;4<;/SP>; - acetyl - sulphanilamido)-, (10) 2 - (p - nitrobenzene - sulphonamido)-, (11) and (13) 2 - (sulphanil - amido)-, (12) 2 - (N<;SP>;4<;/SP>; - acetylsulphanilamido) -, (14) 4 - p - nitrobenzenesulphonamido 2 - methoxy-, (15) 4 - sulphanilamido - 2 - methoxy-, (16) 2 - (p - nitrobenzene - sulphon - amido) 4 - methoxy-, (17) 2 - sulphanilamido- 4 - methoxy-, (18) 2 - (p - nitrobenzene - sulphonamido) - 4, 6 - dimethyl-, (19) 2 - sulphanlamido - 4, 6 - dimethyl-, (20) 2 - N<;SP>;1<;/SP>; - methyl - sulphanilamido-, (21) 4 - p - chloro - benzene - sulphamido-, (this pyrimidine may be reacted with ammonia or amines, e.g. methylamine, aniline or benzyl amine to yield the corresponding substituted 4-N<;SP>;4<;/SP>; pyrimidine), (22) azobenzene - p -, p<;SP>;1<;/SP>; - (di - 2 - sulphon - amido)-, (23) 5 - (N<;SP>;4<;/SP>; - acetylsulphanilamido) - 2 - acetylamino-, (24) 5 - sulphanilamido - 2 - amino, (25) 5 - (p - nitrobenzenesulphonamido) - 2 - methoxy-, (26) 5 - sulphanilamido - 2. - methoxy-, (27) 2 - (N<;SP>;4<;/SP>; - acetylsulphanilamido) - 4 - ethoxy,- (28) 2 - sulphanilamido - 4 - ethoxy, (29) 2, 5 - di (p - nitrobenzene - sulphonamido)-, (30) 2, 5 - disulphanilamido-, (31) 2 - (p - nitrobenzene - sulphonamido) - 5 - chloro-, (32) 2 - sulphanilamido - 5 - chloro-, (33) sodium salt of 2 - sulphanilamido-, (34) copper salt of 2 - sulphanilamido-, (35) the glucose derivative of 2-sulphanilamido- and (36) 2-(N<;SP>;4<;/SP>;-benzylsulphanilamido)-pyrimidine. Examples (35) and (36) relate to two typical samples which have been furnished. The Specification as open to inspection under Sect. 91 states that in some cases the products may also be made by reacting a halogen substituted pyrimidine with an N<;SP>;4<;/SP>;-acylsulphanilamide in the presence of an alkali with subsequent hydrolysis of the acyl group. In examples (23) N<;SP>;4<;/SP>;-acetylsulphanilamide is treated with 2-chloro-4, 6-dimethylpyrimidine in the presence of potassium carbonate and copper powder to yield 2-N<;SP>;4<;/SP>;-acetylsulphanilamido-4, 6-dimethyl pyrimidine which is hydrolysed to the free amine, (24) 2-sulphanilamidopyrimidine is diazotized and coupled with 7-acetylamino-1-hydroxynaphthalene-3, 6-disulphonic acid to yield 4<;SP>;1<;/SP>;-(N-(2-pyrimidyl) sulphonamido) - 2 - azo - 7 - acetylamino - 1 - hydroxynaphthalene - 3, 6 - disulphonic acid and in (29) 2-(N<;SP>;4<;/SP>;-acetylsulphanilamido)-4- methyl - pyrimidine and (30) 2 - sulphanil - amido - 4 - methylpyrimidine are made by methods described above. This subjectmatter does not appear in the Specification as accepted.

    555,865. 磺胺嘧啶。美国氰胺公司。1941年3月8日,编号3174和3175。公约日期,1940年3月1日和1940年10月15日。提供样本。[2类(iii)] p-取代磺酰氨基嘧啶通过将磺酰卤化物(例如,在对位由基或可通过解、还原或与或胺(如酰基,硝基,卤素或偶基)反应转化的基团取代的化物)与氨基嘧啶反应制备。产品的一般公式如下,其中R是卤素,硝基,偶基或取代基,例如烷基基,芳基基,芳基烷基基,酰胺基或单醛基,X是H,烷基基团或属,Py是取代或未取代的嘧啶,n是小整数。单醛氨基化合物通过与单醛糖(例如半乳糖葡萄糖)反应制备相应的氨基化合物而制备,最好在乙醇等溶剂中。在与磺酰卤化物反应过程中产生的游离卤酸通过在碱性介质中进行反应(例如水杨酸钠三乙胺吡啶)和指定的溶剂(例如二噁英,丙酮)中除去。还描述了产品的碱属或重属(例如)盐。示例描述了通过上述方法制备以下化合物(1)5-(N <; SP>; 4 <;/ SP>; -乙酰磺胺基) - 2,4-二羟基-,(2)5-(磺胺基)- 2,4-二羟基-,(3)5-(对-硝基苯磺胺基)- 2,4-二羟基-,(4)5-(N <; SP>; 4 <;/ SP>; -乙酰磺胺基)-,(5)5-(磺胺基)-,(6)4-(对-硝基苯磺胺基)-,(7)和(9)4-(磺胺基)-,(8)4-(N <; SP>; 4 <;/ SP>; -乙酰-磺胺基)-,(10)2-(对-硝基苯-磺胺基)-,(11)和(13)2-(磺胺-基)-,(12)2-(N <; SP>; 4 <;/ SP>; -乙酰磺胺基)-,(14)4-对-硝基苯磺胺2-甲基-,(15)4-磺胺基-2-甲基-,(16)2-(对-硝基苯磺胺基)-4-甲氧基-,(17)2-磺胺基-4-甲氧基-,(18)2-(对-硝基苯磺胺基)-4,6-二甲基-,(19)2-磺胺基-4,6-二甲基-,(20)2-N <; SP>; 1 <;/ SP>; -甲基-磺胺基-,(21)4-对-氯苯-磺胺基-,(该嘧啶可以与或胺(例如甲胺苯胺苄胺)反应,生成相应的取代4-N <; SP>; 4 <;/ SP>; 嘧啶),(22)偶氮苯-对-,p <; SP>; 1 <;/ SP>; -(二-2-磺-基)-,(23)5-(N <; SP>; 4 <;/ SP>; -乙酰磺胺基)-2-乙酰基-,(24)5-磺胺基-2-基,(25)5-(对-硝基苯磺胺基)-2-甲基-,(26)5-磺胺基-2. -甲基-,(27)2-(N <; SP>; 4 <;/ SP>; -乙酰磺胺基)-4-乙基-,(28)2-磺胺基-4-乙基,(29)2,5-二(对-硝基苯-磺胺基)-,(30)2,5-二磺胺基-,(31)2-(对-硝基苯-磺胺基)-5--,(32)2-磺胺基-5--,(33)2-磺胺基-的钠盐,(34)2-磺胺基-的盐,(35)2-磺胺基-的葡萄糖生物和(36)2-(N <; SP>; 4 <;/ SP>; -苄基磺胺基)-嘧啶。示例(35)和(36)涉及
  • [EN] SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA<br/>[FR] INHIBITEURS DE SOX11 POUR TRAITER UN LYMPHOME À CELLULES DU MANTEAU
    申请人:ICAHN SCHOOL MED MOUNT SINAI
    公开号:WO2021257544A1
    公开(公告)日:2021-12-23
    Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.
    公开的是一些化合物,它们是SOX11的化学抑制剂。所公开的化合物在治疗多种癌症方面是有用的。
  • Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
    申请人:Sharpe Arlene H.
    公开号:US20130022629A1
    公开(公告)日:2013-01-24
    Disclosed are an assay to identify modulators of the PD-1:PD-L pathway and PD-1:PD-L pathway modulators, e.g., compounds and pharmaceutical compositions thereof. Methods for treating diseases influenced by modulation of the PD-1:PD-L pathway such as, for example, autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, immune deficiency, and other immune system-related disorders, are also disclosed.
    本发明揭示了一种鉴定PD-1:PD-L途径调节剂的测定方法和PD-1:PD-L途径调节剂,例如,化合物和制药组合物。本发明还揭示了通过调节PD-1:PD-L途径治疗受PD-1:PD-L途径调节影响的疾病的方法,例如自身免疫疾病、炎症性疾病、过敏、移植排斥、癌症、免疫缺陷和其他与免疫系统相关的疾病。
  • Novel Anthraquinone-Based Benzenesulfonamide Derivatives and Their Analogues as Potent Human Carbonic Anhydrase Inhibitors with Antitumor Activity: Synthesis, Biological Evaluation, and In Silico Analysis
    作者:Shanshan Wu、Xiaoping Zhou、Fei Li、Wei Sun、Qingchuan Zheng、Di Liang
    DOI:10.3390/ijms25063348
    日期:——
    In this study, we designed two series of novel anthraquinone-based benzenesulfonamide derivatives and their analogues as potential carbonic anhydrase inhibitors (CAIs) and evaluated their inhibitory activities against off-target human carbonic anhydrase II (hCA II) isoform and tumor-associated human carbonic anhydrase IX (hCA IX) isoform. Most of these compounds exhibited good inhibitory activities
    在本研究中,我们设计了两个系列的新型蒽醌酰胺生物及其类似物作为潜在的碳酸酐酶抑制剂(CAI),并评估了它们对靶人碳酸酐酶II(hCA II)异构体和肿瘤相关人碳酸酐酶的抑制活性。酶 IX (hCA IX) 亚型。大多数这些化合物对 hCA II 和 IX 表现出良好的抑制活性。在低和常条件下,对 MDA-MB-231、MCF-7 和 HepG2 细胞系表现出最佳 hCA 抑制作用的化合物进行了进一步研究。此外,对表现出最佳抗肿瘤活性的化合物进行了细胞凋亡和线粒体膜电位测定,结果显示凋亡细胞的百分比显着增加,细胞活力显着下降。进行分子对接研究以证明化合物与 hCA 活性位点之间存在大量键和疏相互作用。吸收、分布、代谢、排泄(ADME)预测表明所有化合物均具有良好的药代动力学和理化性质。
  • Chemotherapy. II. Some Sulfanilamido Heterocycles<sup>1</sup>
    作者:Richard O. Roblin、James H. Williams、Philip S. Winnek、Jackson P. English
    DOI:10.1021/ja01865a027
    日期:1940.8
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫